Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy

OBJECTIVE: To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19. METHODS: Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included. RESULTS: The results showed that melatoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Kristina M., Landis, Dylan M., Sehgal, Laveena, Payne, J. Drew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AACE. Published by Elsevier Inc. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190272/
https://www.ncbi.nlm.nih.gov/pubmed/34119679
http://dx.doi.org/10.1016/j.eprac.2021.06.001
_version_ 1783705651172605952
author Cross, Kristina M.
Landis, Dylan M.
Sehgal, Laveena
Payne, J. Drew
author_facet Cross, Kristina M.
Landis, Dylan M.
Sehgal, Laveena
Payne, J. Drew
author_sort Cross, Kristina M.
collection PubMed
description OBJECTIVE: To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19. METHODS: Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included. RESULTS: The results showed that melatonin acts to reduce reactive oxygen species–mediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19. CONCLUSION: These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis.
format Online
Article
Text
id pubmed-8190272
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AACE. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-81902722021-06-10 Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy Cross, Kristina M. Landis, Dylan M. Sehgal, Laveena Payne, J. Drew Endocr Pract Review Article OBJECTIVE: To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19. METHODS: Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included. RESULTS: The results showed that melatonin acts to reduce reactive oxygen species–mediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19. CONCLUSION: These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis. AACE. Published by Elsevier Inc. 2021-08 2021-06-10 /pmc/articles/PMC8190272/ /pubmed/34119679 http://dx.doi.org/10.1016/j.eprac.2021.06.001 Text en © 2021 AACE. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Cross, Kristina M.
Landis, Dylan M.
Sehgal, Laveena
Payne, J. Drew
Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title_full Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title_fullStr Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title_full_unstemmed Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title_short Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
title_sort melatonin for the early treatment of covid-19: a narrative review of current evidence and possible efficacy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190272/
https://www.ncbi.nlm.nih.gov/pubmed/34119679
http://dx.doi.org/10.1016/j.eprac.2021.06.001
work_keys_str_mv AT crosskristinam melatoninfortheearlytreatmentofcovid19anarrativereviewofcurrentevidenceandpossibleefficacy
AT landisdylanm melatoninfortheearlytreatmentofcovid19anarrativereviewofcurrentevidenceandpossibleefficacy
AT sehgallaveena melatoninfortheearlytreatmentofcovid19anarrativereviewofcurrentevidenceandpossibleefficacy
AT paynejdrew melatoninfortheearlytreatmentofcovid19anarrativereviewofcurrentevidenceandpossibleefficacy

Ejemplares similares